Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats.
It is shown that daily oral administration of 5--10 mg of an antidiabetic biguanide-phenformin (phenethyl-biguanide) for 2.5--5 months suppressed DMBA-induced mammary tumour development in rats considerably. Phenformin-treated rats revealed-a tendency towards a decrease in blood insulin level (radioimmunoassay). The obtained data are regarded as additional evidence for the proposed existence of the same metabolic background of diseases of compensation, i.e. adult-onset diabetes, artherosclerosis and cancer, and suggest studies on possible antitumour effect of phenformin in man.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood; D007328:Insulin / Q000097:blood; D008325:Mammary Neoplasms, Experimental / Q000517:prevention & control*; D010629:Phenformin / Q000627:therapeutic use*; D051381:Rats
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D015127:9,10-Dimethyl-1,2-benzanthracene; D002784:Cholesterol; D010629:Phenformin